

This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Various				
Inflammation; sepsis	Nuclear receptor subfamily 0 group B member 2 (NR0B2; SHP)	<p>Mouse and cell culture studies suggest increasing SHP activity could help treat sepsis and inflammation. In a mouse model of lipopolysaccharide (LPS)-induced septic shock, <i>Shp</i> deficiency resulted in lower survival than <i>Shp</i> expression ($p < 0.01$). In bone marrow-derived macrophages, <i>Shp</i> overexpression decreased LPS-induced expression of proinflammatory cytokines compared with what was seen using a control vector ($p < 0.001$). Next steps could include identifying compounds that could increase SHP signaling and evaluating the molecules in animal models of inflammation and sepsis.</p> <p>SciBX 4(28); doi:10.1038/scibx.2011.806 Published online July 21, 2011</p>	Patent and licensing status unavailable	<p>Yuk, J.-M. <i>et al. Nat. Immunol.</i>; published online July 3, 2011; doi:10.1038/ni.2064</p> <p>Contact: Eun-Kyeong Jo, Chungnam National University School of Medicine, Daejeon, South Korea e-mail: hayoungj@cnu.ac.kr</p> <p>Contact: Hueng-Sik Choi, same affiliation as above e-mail: hsc@chonnam.ac.kr</p>